Back to Results

Agomab Therapeutics Nv (AGMB)

-


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-AGMB
$12.63
3.8% Upside
Fair
$37.67
209.5% Upside
Bargain
Good
0.0%
December 2, 2026
5.6x
599.3 M
503 M
0.2%
28.1%
15.8
69.5%
Valuation • Fair Value

Agomab Therapeutics Nv (NASDAQ-AGMB) Fair Value by Valuation Model

Review the available estimates for Agomab Therapeutics Nv (NASDAQ-AGMB), including Comps Fair Value.

Primary Valuation Read

Fair Value

$12.63

Estimated upside of 3.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$12.63

Comparable-company valuation reference.

Analyst Price Target

$37.67

Analysts imply upside of 209.5%.

How to read these valuation models

Use the 4 available valuation references for Agomab Therapeutics Nv (NASDAQ-AGMB) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Agomab Therapeutics Nv (NASDAQ-AGMB)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-74.867 M

Current operating profitability reference.

EBITDA Forecast

-91.087 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Agomab Therapeutics Nv (NASDAQ-AGMB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Agomab Therapeutics Nv (NASDAQ-AGMB)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

15.8

Relatively strong balance-sheet zone.

FCF / Net Income

69.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Agomab Therapeutics Nv (NASDAQ-AGMB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Agomab Therapeutics Nv (NASDAQ-AGMB)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 2, 2026

Days to Earnings

75

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Agomab Therapeutics Nv (NASDAQ-AGMB), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Agomab Therapeutics Nv (NASDAQ-AGMB) Stock Forecast & Technical Outlook

Review Agomab Therapeutics Nv (NASDAQ-AGMB) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Agomab Therapeutics Nv (NASDAQ-AGMB) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Agomab Therapeutics Nv (NASDAQ-AGMB) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Agomab Therapeutics Nv (NASDAQ-AGMB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Agomab Therapeutics Nv (NASDAQ-AGMB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Agomab Therapeutics Nv (NASDAQ-AGMB) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Agomab Therapeutics Nv (NASDAQ-AGMB)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Agomab Therapeutics Nv (NASDAQ-AGMB) has a Strong Buy consensus, with 4 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 4
Hold 0
Sell 0
FAQ • Fast Investor Answers

Agomab Therapeutics Nv (NASDAQ-AGMB) Stock FAQ

Data-supported answers about Agomab Therapeutics Nv (NASDAQ-AGMB), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$12.63
Estimated upside 3.8%
Valuation Rating
Undervalued
Estimated upside of 3.8%
Analyst Target
$37.67
Implied upside 209.5%
Financial Health
Good
Current financial-health read

The current fair value estimate for Agomab Therapeutics Nv (NASDAQ-AGMB) is $12.63. This implies an estimated upside of 3.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 3.8% versus the current market price.

The available analyst price target for Agomab Therapeutics Nv (NASDAQ-AGMB) is $37.67. The analyst target implies estimated upside of 209.5%.

The current financial health read for Agomab Therapeutics Nv (NASDAQ-AGMB) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Agomab Therapeutics Nv (NASDAQ-AGMB) is December 2, 2026.

The latest available data indicates no current dividend yield for Agomab Therapeutics Nv (NASDAQ-AGMB).

The current market capitalization listed for Agomab Therapeutics Nv is 599.3 M.

The current enterprise value listed for Agomab Therapeutics Nv is 503 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Agomab Therapeutics Nv is NASDAQ-AGMB, and the stock is listed on NASDAQ.

Agomab Therapeutics Nv (NASDAQ-AGMB) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Agomab Therapeutics Nv is 0.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Agomab Therapeutics Nv is 28.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B